Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Giusi M Bellistrì

T-Cell Phenotype and Function Following a First cART Regimen Containing Either a Protease Inhibitor or a Non-Nucleoside Retrotranscriptase Inhibitor in HIV-infected Late Presenters: Results From a Retrospective, Ex Vivo Study

Antiviral Therapy

Infectious Diseases

Pharmacology

2015

English

Related publications

Immune Reconstitution Inflammatory Syndrome in HIV Infected Late Presenters Starting Integrase Inhibitor Containing Antiretroviral Therapy

EClinicalMedicine

Medicine

2019

English

First-Line Antiretroviral Therapy With a Protease Inhibitor Versus Non-Nucleoside Reverse Transcriptase Inhibitor and Switch at Higher Versus Low Viral Load in HIV-infected Children: An Open-Label, Randomised Phase 2/3 Trial

The Lancet Infectious Diseases

Infectious Diseases

2011

English

Viral Resuppression and Detection of Drug Resistance Following Interruption of a Suppressive Non-Nucleoside Reverse Transcriptase Inhibitor-Based Regimen

English

Maraviroc 150 Mg Daily Plus Lopinavir/Ritonavir, a Nucleoside/Nucleotide Reverse Transcriptase Inhibitor-Sparing Regimen for HIV-infected Naive Patients: 48-Week Final Results of VEMAN Study

Clinical Microbiology and Infection

English

Development of a Vaginal Delivery Film Containing EFdA, a Novel Anti-Hiv Nucleoside Reverse Transcriptase Inhibitor

International Journal of Pharmaceutics

Pharmaceutical Science

2014

English

482 GRL-142, a Novel HIV-1 Protease Inhibitor, Potently Blocks HIV-1 Ex Vivo Infection of Langerhans Cells Within Epithelium

Journal of Investigative Dermatology

English

KNI-102, a Novel Tripeptide HIV Protease Inhibitor Containing Allophenylnorstatine as a Transition-State Mimic.

Chemical and Pharmaceutical Bulletin

English

A Protease Inhibitor From Penicillium Cyclopium

Agricultural and Biological Chemistry

1969

English

TheEx VivoHuman Placental Transfer of the Anti-Hiv Nucleoside Inhibitor Abacavir and the Protease Inhibitor Amprenavir

Infectious Diseases in Obstetrics and Gynecology

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Giusi M Bellistrì

T-Cell Phenotype and Function Following a First cART Regimen Containing Either a Protease Inhibitor or a Non-Nucleoside Retrotranscriptase Inhibitor in HIV-infected Late Presenters: Results From a Retrospective, Ex Vivo Study

Related publications

Immune Reconstitution Inflammatory Syndrome in HIV Infected Late Presenters Starting Integrase Inhibitor Containing Antiretroviral Therapy

First-Line Antiretroviral Therapy With a Protease Inhibitor Versus Non-Nucleoside Reverse Transcriptase Inhibitor and Switch at Higher Versus Low Viral Load in HIV-infected Children: An Open-Label, Randomised Phase 2/3 Trial

Viral Resuppression and Detection of Drug Resistance Following Interruption of a Suppressive Non-Nucleoside Reverse Transcriptase Inhibitor-Based Regimen

Maraviroc 150 Mg Daily Plus Lopinavir/Ritonavir, a Nucleoside/Nucleotide Reverse Transcriptase Inhibitor-Sparing Regimen for HIV-infected Naive Patients: 48-Week Final Results of VEMAN Study

Development of a Vaginal Delivery Film Containing EFdA, a Novel Anti-Hiv Nucleoside Reverse Transcriptase Inhibitor

482 GRL-142, a Novel HIV-1 Protease Inhibitor, Potently Blocks HIV-1 Ex Vivo Infection of Langerhans Cells Within Epithelium

KNI-102, a Novel Tripeptide HIV Protease Inhibitor Containing Allophenylnorstatine as a Transition-State Mimic.

A Protease Inhibitor From Penicillium Cyclopium

TheEx VivoHuman Placental Transfer of the Anti-Hiv Nucleoside Inhibitor Abacavir and the Protease Inhibitor Amprenavir